Karkinos : Karkinos Healthcare Pvt. Ltd. is a purpose-driven oncology platform using innovative technologies for personalized cancer care. Driven by eminent medical professionals and technology, it aims to create ‘cancer centers without boundaries’ to address accessibility and affordability gaps. The platform integrates revolutionary oncology-focused technology, diagnostic network, and care centers, dedicating a significant share to advance oncology research, education, and patient care.
Medgenome : MedGenome, a global pioneer in genetic testing, genomics, and drug development, is dedicated to providing high-quality genomic solutions with enhanced precision. Our mission is to democratize access to accurate and affordable genetic testing, addressing healthcare needs worldwide and ensuring broader accessibility to advanced genetic solutions for improved diagnosis of complex disorders.
Illumina: Illumina is transforming genomic analysis through cutting-edge technology, enabling unprecedented studies. Our goal is to offer customers adaptable, scalable solutions emphasizing global collaboration, rapid delivery, and high quality. As a global leader, Illumina’s pioneering sequencing and array technologies drive breakthroughs in life science research, translational genomics, consumer genomics, and molecular diagnostics, addressing challenges in our evolving field and making substantial contributions to genomics.
Datar cancer genetics: Datar Cancer Genetics pioneers early cancer detection through innovative blood-based diagnostics. Focused on precision medicine, we leverage genomic data to personalize treatment, aiming to improve therapeutic outcomes and contribute to a deeper understanding of cancer genetics. Our commitment is anchored in persistent research, bold initiatives, and an unwavering drive to conquer cancer.
ImmunoAct: ImmunoACT, a national leader in Cell & Gene Therapy, spearheads groundbreaking research, particularly in CAR-T cell therapy, striving for accessible cures. Committed to making innovative treatments inclusive and affordable, our mission is to transform ideas into globally impactful therapies, redefining cancer care and envisioning a future where transformative solutions provide accessible and affordable care worldwide.
Oncosure: We at ONCOSure believe in democratizing Precision Medicine for Oncology and are of the firm opinion that the amalgamation of AI and Precision Medicine can bring immense benefits in terms of improved treatment outcomes, lowering costs of treatment and improved life expectancy in patients. It is our mission to use the immense power of AI to provide doctors with all the tools needed to reach the most favorable decision on treatment within the shortest timeframe, armed with the evidence from the leading researches all across the world. We cannot eradicate Cancer, but we can at least put all our might together to fight it.
HaystackAnalytics: HaystackAnalytics, a HealthTech innovator, specializes in clinical genomics, transforming diagnostic capabilities for labs and hospitals. Their solutions enable precise and personalized diagnostics, emphasizing infectious diseases. Recognized for top innovations like the Tuberculosis genomics test, HaystackAnalytics addresses critical healthcare challenges. Committed to global health goals, their Universal ID solution aligns with WHO’s Sustainable Development Goal, showcasing dedication to advancing healthcare worldwide.
Qiagen: Qiagen, a global leader in molecular diagnostics and life sciences, is revolutionizing healthcare through pioneering contributions. With a focus on precision medicine, infectious disease management, and cancer research, Qiagen’s technologies enable personalized treatment plans and rapid disease detection. Automated sample processing, bioinformatics solutions and global collaborations underscore its commitment to transformative advancements in the healthcare sector.
Cepheid: Cepheid is a pivotal force in reshaping personalized medicine within the healthcare industry. Renowned for its innovative molecular diagnostic systems, Cepheid facilitates rapid and precise identification of infections and genetic markers. Empowering healthcare practitioners with real-time diagnostic information, Cepheid revolutionizes treatment personalization, contributing to a healthcare landscape that is more personalized, efficient, and effective.
BioMérieux: BioMérieux revolutionizes healthcare enterprises through unique diagnostic solutions. Offering innovative tools and assays, the company empowers healthcare professionals to make informed treatment decisions. Rooted in combating infectious diseases, bioMérieux excels in early detection tests, showcasing expertise in addressing antibiotic resistance and healthcare-associated illnesses. Actively engaged in research for emerging diseases, the company elevates diagnostic capabilities, contributing to a higher global healthcare standard.
Qure.ai: Qure.ai, a healthcare technology entity, employs artificial intelligence to analyze medical images, specializing in AI-based radiology solutions. Their goal is to enhance diagnostic capabilities and patient outcomes. Qure.ai’s algorithms assist radiologists in evaluating medical imaging data by detecting and analyzing anomalies and clinically significant information. Through AI, they accelerate diagnostics, enhance accuracy, and contribute to more efficient healthcare delivery.
